Phio to Present Phase 1b PH-762 Data with 65% cSCC Response and 85% Highest-Dose Response
Phio's Phase 1b trial of intratumoral PH-762 in 22 patients showed a 65% pathological response rate in cutaneous squamous cell carcinoma, including an 85% response in the highest-dose cohort, with no serious adverse events. The company plans FDA engagement in Q2 2026 and has cash runway into mid-2027.
1. Presentation at American Academy of Dermatology
Phio will deliver a podium presentation on March 28, 2026 in Denver at the Late-Breaking Research Session S034, detailing results from its escalating dose study of intratumoral PH-762 for cutaneous carcinomas.
2. Phase 1b Clinical Results
The open-label trial enrolled 22 patients across five dose-escalation cohorts, reporting no dose-limiting toxicities or serious adverse events, a 65% pathological response rate in cSCC overall and an 85% response in the highest-dose cohort, with modest mean tumor burden reductions.
3. Regulatory Engagement and Financial Runway
Phio targets FDA engagement in the second quarter of 2026 to discuss next-stage clinical development of PH-762 and maintains cash and cash equivalents projected to fund operations into the first half of 2027.
4. INTASYL Technology and Pipeline Outlook
PH-762 leverages Phio’s INTASYL self-delivering RNAi platform to silence the PD-1 gene in tumor tissue, representing a non-surgical immuno-oncology approach and positioning Phio for further clinical advancement in skin cancers.